The ScHARR Technology Assessment Group (ScHARR-TAG) is part of a wider collaboration who undertake reviews for National Institute for Health and Care Excellence (NICE) and National Institute for Health Research (NIHR).
Work for NICE
|Multiple Technology Appraisals (MTAs)||
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111].
Non Bisphospenates for Osteoporosis. Review of (TA160, TA161, TA204) [ID901].
|Single Technology Appraisals (STAs)||
Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]
Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]
Gilteritinib for treating relapsed or refractory acute myeloid leukaemia [ID1484]
Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older [ID1195].
Trifluridine–tipiracil for treating metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID1507].
Clostridium botulinum neurotoxin type A for treating hypersalivation associated with neurological conditions [ID1150].
Pentosan polysulfate sodium for treating bladder pain syndrome [ID1364].
Olaparib for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after response to initial platinum-based chemotherapy [ID1124].
Pembrolizumab with carboplatin and paclitaxel for untreated squamous non-small-cell lung cancer [ID1306].
Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].
Blinatumomab for treating B-precursor, minimal residual remission acute lymphoblastic leukaemia [ID1036].
Nusinersen for treating infant or child spinal muscular atrophy [ID1069].
Regorafenib after sorafenib, for treating unresectable hepatocellular carcinoma [ID991].
Sarilumab after TNFnhibitors for treating active rheumatoid arthritis [ID994].
Cx601 for treating complex perianal fistula in non-active or mildly-active luminal Crohn’s disease [ID960].
|Diagnostic Assessment Reports (DARs)||
The EndoPredict multigene test for guiding therapy decisions in breast cancer management 16/30/03.
|Fast Track Assessments (FTAs)||
Pembrolizumab for locally advanced or metastatic urothelial cancer where cisplatin is unsuitable [ID1209].
Golimumab after NSAIDs for severe, active, non-radiographic, Axial spondyloarthritis [ID903].
|Highly Specialised Technologies (HSTs)||
Volanesorsen for treating familial chylomicronaemia syndrome [ID1326].
Patisiran for treating hereditary transthyretin-related amyloidosis [ID1279].
Recombinant human alpha-mannosidase for treating alpha-mannosidosis [ID800].
Work for NIHR
Modelling approaches for site-agnostic cancer drugs to inform NICE appraisal [NIHR127852]
Review on patient safety and reduction of risk of transmission of Creutzfeldt-Jakob disease (CJD) [17/48/01].
For additional topics in the fields see the right hand side.